Results 31 to 40 of about 4,732,777 (361)

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

Journal of Hematology & Oncology, 2022
Background Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited.
Z. Zhou, Z. Ding, J. Yuan, S. Shen, H. Jian, Q. Tan, Yu-Chung Yang, Z. Chen, Q. Luo, X. Cheng, Y. Yu, X. Niu, L. Qian, X. Chen, L. Gu, R. Liu, S. Ma, J. Huang, T. Chen, Z. Li, W. Ji, L. Song, L. Shen, L. Jiang, Z. Yu, C. Zhang, Z. Tai, C. Wang, R. Chen, S. Lu   +29 more
semanticscholar   +1 more source

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Biomarker Research, 2023
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patients with unresectable NSCLC.
Luis A. Godoy, Joy Y. Chen, Weijie Ma, Jag Lally, K. Toomey, P. Rajappa, Roya Sheridan, Shirish Mahajan, N. Stollenwerk, C. Phan, Danny Cheng, R. Knebel, Tianhong Li   +12 more
semanticscholar   +1 more source

Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?

Annals of Gastroenterological Surgery, 2020
Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy.
Fuyuhiko Motoi, Michiaki Unno
doaj   +1 more source

Visual analysis of the research hotspots in neoadjuvant therapy for patients with gastric cancer

Frontiers in Gastroenterology, 2023
ObjectiveThis study aimed to analyze the research hotspots and frontiers in the field of neoadjuvant therapy for patients with gastric cancer (GC) using bibliometric and identify its developmental trends.MethodsThe literature related to neoadjuvant ...
Tianxing Chen, Tianxing Chen, Yating Liu, Yating Liu, Jing Gao, Dekui Zhang, Dekui Zhang   +6 more
doaj   +1 more source

Rectal MRI Interpretation After Neoadjuvant Therapy

Journal of Magnetic Resonance Imaging, 2022
In recent years, several key advances in the management of locally advanced rectal cancer have been made, including the implementation of total mesorectal excision as the standard surgical approach; use of neoadjuvant chemoradiotherapy in selected ...
N. Horvat, Maria El Homsi, Joao Miranda, Y. Mazaheri, M. Gollub, V. Paroder   +5 more
semanticscholar   +1 more source

Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma

Frontiers in Immunology, 2023
PurposeIn patients with resectable esophageal squamous cell carcinoma (ESCC), neoadjuvant therapy increased the curative resection rate, disease-free survival, and overall survival for patients with resectable ESCC.
Xin Nie, Shuya He, Xinming Nie, Changding Li, Kunyi Du, Wenwu He, Zhiyu Li, Kunhan Ni, Simiao Lu, Chenghao Wang, Kangning Wang, Yan Miao, Longlin Jiang, Jiahua Lv, Guangyuan Liu, Qiang Fang, Lin Peng, Wenguang Xiao, Qifeng Wang, Dongsheng Wang, Yongtao Han, Xuefeng Leng   +21 more
doaj   +1 more source

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

Therapeutic Advances in Medical Oncology, 2022
The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy.
R. Witt, Derek J. Erstad, J. Wargo
semanticscholar   +1 more source

The Role of VEGFA, COX2, HUR and CUGBP2 in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients

Medicina, 2020
Background and objectives: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the
Henrikas Pauzas, Ugne Gyvyte, Tadas Latkauskas, Laura Kairevice, Paulius Lizdenis, Saulius Svagzdys, Erika Birgiolaite, Irma Kuliaviene, Juozas Kupcinskas, Algimantas Tamelis   +9 more
doaj   +1 more source

Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy

Bioactive Materials, 2023
Surgical resection remains a mainstay in the treatment of malignant solid tumors. However, the use of neoadjuvant treatments, including chemotherapy, radiotherapy, phototherapy, and immunotherapy, either alone or in combination, as a preoperative ...
Xiaogang Qu, Dong Zhou, Jianpu Lu, Duotian Qin, Jun Zhou, Hai-Jun Liu   +5 more
doaj   +1 more source

Neoadjuvant Therapy for Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma, 2022
Hepatocellular carcinoma (HCC) is characterized by low resection and high postoperative recurrence rates, and conventional treatment strategies have failed to meet clinical needs.
Zongyi Yin, Dongying Chen, Shuang Liang, Xiaowu Li   +3 more
semanticscholar   +1 more source